Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial

The Lancet Oncology

Volumn 17, Issue 1, 2016, Pages 78-89

  Bois, Andreas du ^a,b   Kristensen, Gunnar ^c   Ray Coquard, Isabelle ^e   Reuss, Alexander ^d   Pignata, Sandro ^f   Colombo, Nicoletta ^g,h   Denison, Ursula ⁱ   Vergote, Ignace ^j   del Campo, Jose M ^k   Ottevanger, Petronella ^l   Heubner, Martin ^m   Minarik, Thomas ⁿ   Sevin, Emmanuel ^o   de Gregorio, Nikolaus ^p   Bidziński, Mariusz ^q   Pfisterer, Jacobus ^r   Malander, Susanne ^s   Hilpert, Felix ^t   Mirza, Mansoor R ^u   Scambia, Giovanni ^v   Meier, Werner ^w   Nicoletto, Maria O ^x   Bjørge, Line ^y   Lortholary, Alain ^z   Sailer, Martin Oliver ^z   Merger, Michael ^z   Harter, Philipp ^a,b   more..

^a KLINIKEN ESSEN MITTE   (Germany)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITÉ DE LYON   (France)

^d AGO and Coordinating Center for Clinical Trials   (Germany)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

^g EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^h University Hospitals Leuven ^*  (Austria)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY HOSPITAL ESSEN   (Germany)

^m National Institute of Oncology   (Slovakia)

ⁿ CENTRE FRANÇOIS BACLESSE   (France)

^o UNIVERSITY HOSPITAL ULM   (Germany)

^p JAN KOCHANOWSKI UNIVERSITY   (Poland)

^q Gynecologic Oncology Center Kiel   (Germany)

^r LUND UNIVERSITY HOSPITAL   (Sweden)

^s UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^t University of Copenhagen   (Denmark)

^u UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^v Children s Hospital   (Germany)

^w VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^x HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^y Center Catherine de Sienne   (France)

^z BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; NINTEDANIB; PACLITAXEL; PLACEBO; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARM PAIN; ARTERIAL THROMBOEMBOLISM; ARTHRALGIA; ARTICLE; ASCITES; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSGEUSIA; DYSPNEA; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; ILEUS; INCIDENCE; INSOMNIA; KIDNEY FAILURE; LEG PAIN; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASM PROGRESSION; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PERITONITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; THROMBOCYTOPENIA; THROMBOSIS; TIME TO TREATMENT; TREATMENT DURATION; TUMOR DIFFERENTIATION; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM; VOMITING; AGED; CARCINOMA; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; MULTICENTER STUDY; OVARIAN NEOPLASMS; PATHOLOGY; PERITONEAL NEOPLASMS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CYTOREDUCTION SURGICAL PROCEDURES; DIARRHEA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; INDOLES; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 84955299214     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00366-6     Document Type: Article

References (31)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-1403.
2. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014, 15:23-34.
3. Oberaigner W, Minicozzi P, Bielska-Lasota M, et al. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol 2012, 51:441-453.
4. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009, 115:1234-1244.
5. Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011, 21:750-755.
6. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003, 95:1320-1329.
7. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000, 18:3084-3092.
8. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:3194-3200.
9. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009, 27:1419-1425.
10. Chan J, Brady M, Penson R, et al. Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712). Int J Gynecol Cancer 2013, 23(8 suppl 1):9-10. (abstr).
11. du Bois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 2006, 24:1127-1135.
12. du Bois A, Herrstedt J, Hardy-Bessard AC, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010, 28:4162-4169.
13. Hoskins P, Vergote I, Cervantes A, et al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst 2010, 102:1547-1556.
14. Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24(suppl 6):vi24-vi32.
15. Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006, 98:1036-1045.
16. Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2014, 15:396-405.
17. Zand B, Coleman RL, Sood AK Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am 2012, 26:543-563. viii.
18. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483.
19. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496.
20. Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 2015, 16:928-936.
21. Heitz F, Harter P, Barinoff J, et al. Bevacizumab in the treatment of ovarian cancer. Adv Ther 2012, 29:723-735.
22. du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014, 32:3374-3382.
23. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008, 68:4774-4782.
24. Doebele RC, Conkling P, Traynor AM, et al. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2012, 23:2094-2102.
25. du Bois A, Huober J, Stopfer P, et al. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 2010, 21:370-375.
26. Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011, 29:3798-3804.
27. Kenward MG, Roger JH Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 1997, 53:983-997.
28. Cocks K, King MT, Velikova G, et al. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 2011, 29:89-96.
29. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007, 6:2012-2021.
30. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483.
31. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014, 15:143-155.